Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.375
Bid: 7.25
Ask: 7.50
Change: 0.00 (0.00%)
Spread: 0.25 (3.448%)
Open: 7.375
High: 7.375
Low: 7.375
Prev. Close: 7.375
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TSB Grant to Develop Dementia Diagnosis Products

13 Dec 2013 07:00

RNS Number : 4517V
IXICO plc
13 December 2013
 



 

IXICO Awarded Technology Strategy Board Grant to Support the Development of Dementia Diagnosis Products

 

13 December 2013, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, today announces that it has been awarded a Stratified Medicine Grant by the UK's innovation agency, the Technology Strategy Board to provide funding to support the development of products to address the global dementia challenge.

 

The grant has been awarded under the Technology Strategy Board's recently launched 'Advancing In-Vivo Imaging for Stratified Medicine' competition. 

 

For this project, a consortium led by IXICO, which includes Imperial College, London as a research partner, Medimmune Limited (the global biologics research and development arm of AstraZeneca) and a second leading global pharmaceutical company as commercial partners, will apply a machine learning framework to a unique combination of reference data to develop a digital dementia prognosis tool. This will use commonly collected diagnostic information (including MRI scans and cognitive, functional and demographic data) to stratify patients based on their expected rate of decline. This could help with the diagnosis of dementia in the clinic and also with the enrichment of patient populations enrolled in clinical trials of investigational drugs, potentially improving the likelihood of measuring a therapeutic effect.

 

Several further global pharmaceutical companies have expressed interest joining the project as collaborators, and contributing clinical trial data in due course. The total value of the 24 month research project is approximately £1 million. The value of the grant is £633,962 of which £456,956 is allocated to IXICO and the remainder to Imperial College. The pharmaceutical partners and collaborators are contributing scientific resources from their R&D teams and access to data from completed clinical trials.

 

This brings the total grant funding secured by IXICO in the last 18 months to approximately £2.6 million of which approximately £2.4 million remains to be drawn down by IXICO.

 

This week the Technology Strategy Board features IXICO, the "Dementia Champions", as its Success Story www.innovateuk.org/success-stories detailing a funding story that stretches back 5 years.

 

Professor Derek Hill, Chief Executive of IXICO commented: "We are pleased to have been awarded this Technology Strategy Board grant. IXICO's products and services are focused on three overlapping areas within clinical trials, experimental medicine and diagnostics; the scope of this project will benefit our work in each. We look forward to working with Imperial and our commercial collaborators to develop important tools with the potential to improve clinical diagnosis of dementia and accelerate the development of effective treatments for Alzheimer's disease."

 

 

Enquiries

 

IXICO plc

+44 207 691 2064

Derek Hill, CEO

Charles Spicer, VP Corporate Development

 

Peel Hunt LLP (Nominated Adviser and broker)

+44 207 418 8900

James Steel

Vijay Barathan

Harry Florry

 

FTI Consulting Limited (U.K. Investor Relations)

+44 207 831 3113

John Dineen

Simon Conway

 

 

About IXICO

IXICO, the brain health company, was founded in 2004 with a mission to translate image acquisition, management and analysis technology and know-how, which the founders had developed together, into commercial products targeting the expanding area of imaging to inform decision-making during drug development. This has resulted in commercially successful products being launched in the clinical trials (Phase 0-III) and experimental medicine markets and being readied for launch into the wider clinical diagnostic market. Since incorporation, IXICO has been contracted by seven of the top 15 global pharmaceutical companies as well as leading biotechnology companies. In October 2013, IXICO plc was admitted to trading on AIM. More information is available on www.ixico.com

 

About the Technology Strategy Board

The Technology Strategy Board is the UK's innovation agency. Its goal is to accelerate economic growth by stimulating and supporting business-led innovation. Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit www.innovateuk.org

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCKMMMZZZRGFZZ
Date   Source Headline
2nd Mar 20108:25 amRNSNotice of AGM
11th Feb 20107:00 amRNSInterim Management Statement
15th Jan 20107:00 amRNSDirectorate Change
5th Jan 20109:10 amRNSHolding(s) in Company
4th Jan 201010:29 amRNSTotal Voting Rights
31st Dec 20099:26 amRNSDirector/PDMR Shareholding
31st Dec 20099:25 amRNSDirector/PDMR Shareholding
31st Dec 20099:25 amRNSDirector/PDMR Shareholding
31st Dec 20099:25 amRNSDirector/PDMR Shareholding
29th Dec 20093:27 pmRNSResult of EGM
22nd Dec 20097:00 amRNSResult of Open Offer
15th Dec 20093:12 pmRNSCorrection to the Form of Proxy
15th Dec 20099:00 amRNSAnnual Information Update
14th Dec 20097:00 amRNSPresents data at XVIII WFN World Congress
3rd Dec 20095:18 pmRNSPublication of Prospectus
3rd Dec 20097:05 amRNSPlacing and Open Offer to Raise ?25.2 million
3rd Dec 20097:00 amRNSReport and Accounts 2009 - Part 3
3rd Dec 20097:00 amRNSReport and Accounts 2009 - Part 2
3rd Dec 20097:00 amRNSReport and Accounts 2009 - Part 1
12th Nov 20093:59 pmRNSBlocklisting Interim Review
4th Nov 20091:36 pmRNSHolding(s) in Company
23rd Oct 20099:42 amRNSHolding(s) in Company
14th Oct 20097:00 amRNSResearch Update
18th Aug 20097:00 amRNSInterim Management Statement
23rd Jul 20097:00 amRNSRe Agreement
20th May 20097:00 amRNSInterim Results
11th May 200911:12 amRNSBlocklisting Interim Review
5th May 20099:14 amRNSCPT commits to the development of Cogane
20th Apr 20097:00 amRNSResearch Update
13th Mar 20099:58 amRNSResult of AGM
10th Mar 20095:16 pmRNSDirector/PDMR Shareholding
10th Mar 20095:13 pmRNSDirector/PDMR Shareholding
10th Mar 20095:13 pmRNSDirector/PDMR Shareholding
10th Mar 20095:10 pmRNSDirector/PDMR Shareholding
3rd Mar 20095:26 pmRNSAnnual Information Update
19th Feb 20093:42 pmRNSHolding(s) in Company
17th Feb 20094:00 pmRNSHolding(s) in Company
17th Feb 20097:00 amRNSInterim Management Statement
28th Jan 200910:48 amRNSAnnual Report & Accounts and Notice of AGM
19th Dec 20084:41 pmRNSSecond Price Monitoring Extn
19th Dec 20084:37 pmRNSPrice Monitoring Extension
12th Dec 200812:00 pmRNSPortfolio Update
27th Nov 20087:00 amRNSFinal Results
14th Nov 20081:00 pmRNSTrading Statement
13th Nov 20087:00 amRNSBoard Change
11th Nov 200810:09 amRNSDirector/PDMR Shareholding
5th Nov 20081:43 pmRNSBlocklisting Interim Review
9th Oct 20082:45 pmRNSDirector/PDMR Shareholding
10th Sep 20089:27 amRNSDirector/PDMR Shareholding
8th Aug 20083:21 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.